Details of the Drug Reposition

General Information of This Drug (ID: DMYZFNH)

Drug Name
Sapanisertib   DMYZFNH
Synonyms INK-128; MLN0128; INK 128; INK128; INK 128 (MLN0128); TAK-228; UNII-JGH0DF1U03; MLN-0128; JGH0DF1U03
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Breast cancer DIS7DPX1 2C60-2C65 Phase 2 [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Investigative [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02049957) Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer. U.S. National Institutes of Health.
2 Prevent COVID-19 Severity by Repurposing mTOR Inhibitors. 2 April 2020